Note B - CB Oncology Partners - Financial Information (Details) - USD ($) |
3 Months Ended | 6 Months Ended | 12 Months Ended | |||||
|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 |
Mar. 31, 2026 |
Jun. 30, 2025 |
Mar. 31, 2025 |
Jun. 30, 2026 |
Jun. 30, 2025 |
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Patient revenue | $ 1,310,000 | $ 0 | $ 2,707,000 | $ 0 | ||||
| Current assets | 1,828,000 | 1,828,000 | $ 4,484,000 | |||||
| Net loss | (1,532,000) | $ (1,294,000) | (441,000) | $ (424,000) | (2,826,000) | (865,000) | (7,804,000) | $ (2,055,000) |
| EHSHI's equity in income (loss) of CBOP | (0) | (0) | ||||||
| Total assets | 3,917,000 | 3,917,000 | 6,664,000 | |||||
| Current liabilities | 1,337,000 | 1,337,000 | 1,340,000 | |||||
| Deficit | 2,569,000 | $ 4,060,000 | $ 3,787,000 | $ 4,228,000 | 2,569,000 | 3,787,000 | 5,313,000 | $ 4,178,000 |
| Total liabilities and stockholder's deficit | 3,917,000 | 3,917,000 | 6,664,000 | |||||
| CB Oncology Partners ("CBOP") [Member] | ||||||||
| EHSHI's equity in income (loss) of CBOP | (36,000) | (109,000) | ||||||
| CB Oncology Partners ("CBOP") [Member] | ||||||||
| Patient revenue | 808,000 | 696,000 | ||||||
| Current assets | 561,000 | 561,000 | 348,000 | |||||
| Net loss | (119,000) | $ (456,000) | ||||||
| Noncurrent assets | 881,000 | 881,000 | 1,185,000 | |||||
| Total assets | 1,442,000 | 1,442,000 | 1,533,000 | |||||
| Current liabilities | 4,342,000 | 4,342,000 | 4,648,000 | |||||
| Noncurrent liabilities | 3,596,000 | 3,596,000 | 3,263,000 | |||||
| Deficit | (6,496,000) | (6,496,000) | (6,378,000) | |||||
| Total liabilities and stockholder's deficit | $ 1,442,000 | $ 1,442,000 | $ 1,533,000 | |||||
| X | ||||||||||
- Definition Amount of asset recognized for present right to economic benefit. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of asset recognized for present right to economic benefit, classified as current. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of income (loss) for proportionate share of equity method investee's income (loss). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of obligation due after one year or beyond the normal operating cycle, if longer. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|